EntroGen News & Events
2025 Great Lakes Genomic Conference
EntroGen is pleased to announce its participation in the 2025 Great Lakes Genomic Conference (GLGC), taking place on Friday, May 16, 2025, at the Peter Gilgan Centre for Research and Learning in Toronto, Ontario. As part of our ongoing commitment to advancing...
EntroGen Receives CMS Coverage for CRCdx® RAS Mutation Detection Kit
Apr 28, 2025 – EntroGen announced today that its CRCdx® RAS Mutation Detection Kit has received national coverage from the US Centers for Medicare & Medicaid Services (CMS).
Visit us at ESMO Congress 2023
EntroGen will be exhibiting at the ESMO Congress 2023 in Madrid, Spain on October 20-23, 2023. Visit EntroGen at Booth 709, Hall 7.
Visit us at AMP2023 Annual Meeting & Expo
November 14-18, 2023. Visit booth #924.
EntroGen Receives FDA Approval for CRCdx® RAS Mutation Detection Kit as Companion Diagnostic for Vectibix®
October 2, 2023 – The U.S. Food and Drug Administration (FDA) has granted approval for EntroGen’s CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix® (panitumumab), a targeted therapy used in the treatment of colorectal cancer.
Alternatives to RNA Fusion Gene Webinar
October 12, 2022 11am PDT | 2pm EDT
Join Us At AMP 2022
Nov 1-5, 2022
MGMT Webinar
January 27, 2022 11am PST | 2pm EST
EntroGen Launches NGS Targeted Hotspot Panel
January 13, 2020
USC and EntroGen to study clinical utility of EntroGen’s liquid biopsy solutions for lung cancer
Today EntroGen Inc. announced that it has entered into a clinical collaboration with University of Southern California Norris Comprehensive Cancer Center to conduct an observational study to determine the clinical utility of EntroGen’s liquid biopsy solutions for lung cancer patients.
EntroGen Newsletter
Receive quarterly updates on EntroGen news and products.